Scienture (SCNX)
Specialty drug developer commercializing differentiated formulations for cardiovascular and CNS care.
Something off on this page? Send us feedback.
Develops cardiovascular and CNS medicines in the United States, selling ARBLI through wholesale distribution and holding commercialization rights for REZENOPY. Its model differentiates established molecules through formulations and delivery systems while outsourcing manufacturing, sales, logistics, and much of distribution.
Develops and commercializes differentiated formulations and delivery systems for cardiovascular and central-nervous-system medicines in the United States. ARBLI, a ready-to-use losartan oral suspension, is its only reported revenue-generating product; REZENOPY, a naloxone nasal spray, is licensed for U.S. commercialization. The pipeline comprises SCN-104 for migraine and cluster-headache episodes, SCN-106 for occluded central venous access devices, and SCN-107 for postoperative pain.
Uses established molecules and drug-delivery formats to address specific care settings, then routes products through wholesalers, pharmacies, and other third-party channels. Operates with contract manufacturers, a contract sales organization, third-party logistics, and licensed rights rather than owned manufacturing facilities. Product uptake depends on FDA approvals, reimbursement and formulary access, and third-party manufacturing and distribution.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.2M · Total debt $10.7M · Total assets $87.7M · Shareholders' equity $64.1M
- Revenue
- $343.6K
- Operating income
- −$2.7M
- Net income
- −$2.8M
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 19, 2024 | Jul 19 | Jul 24 | $1.50 | special dividend |
| Mar 25, 2024 | Mar 18 | $8.00 |
| Institutions14 holders · as of Mar 31, 2026 | 3.46% | 1.42M shares | |
| Insiders2 holders · as of Mar 12, 2026 | 16.65% | 6.84M shares | |
| Otherremainder | 79.89% | 32.81M shares |
41.06M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Hariharan ShankarInsiderdirector, 10 percent owner, officer: Co-CEO & Chairman | 9.47% | 3.89M | Form 4filed Mar 12, 2026 ↗ |
Mani NarasimhanInsiderdirector, officer: President & Co-CEO | 7.17% | 2.95M | Form 4filed Mar 12, 2026 ↗ |
Geode Capital Management, LLCInstitution | 1.05% | 432,186 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 0.99% | 408,091 | 13Fas of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.48% | 198,060 | 13Fas of Mar 31, 2026 |
| See all 18 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Emergent BioSolutions
Leading 4 mg OTC naloxone alternative with broad public-health reach.
- Teva (ADR)
Generic losartan tablets offer a low-cost hypertension alternative.
- Pacira BioSciences
Long-acting bupivacaine competes in non-opioid postsurgical pain.
- AbbVie
Large migraine portfolio overlaps with acute self-treatment options.
- Pfizer
NURTEC ODT contests acute migraine treatment in the pipeline.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Scienture | $0.3810 | +2.97% | $15.0M | — | — | 18.3 | — |
| Emergent BioSolutions | $6.42 | −0.70% | $333.3M | — | — | 0.4 | +66.3% |
| Teva (ADR) | $37.45 | −0.05% | $43.66B | 62.5 | 13.3 | 2.4 | −0.8% |
| Pacira BioSciences | $26.45 | −0.41% | $1.05B | 75.7 | 8.5 | 1.4 | +6.2% |
| AbbVie | $261.07 | −0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Median | 68.1 | 11.8 | 2.4 | +6.2% |